UROPHARMA, INC.
Get an alert when UROPHARMA, INC. files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£46K
+3.5% vs 2023
Net assets
£1M
+402.9% vs 2023
Employees
5
+66.7% vs 2023
Profit before tax
—
Period ending 2024-12-31
Net assets
2-year trend · vs Unclassified median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | — | — | |
| Profit before tax | — | — | |
| Net profit | -£321,110 | -£759,742 | |
| Cash | £44,186 | £45,742 | |
| Total assets less current liabilities | £621,817 | £1,248,283 | |
| Net assets | £235,551 | £1,184,529 | |
| Equity | £235,551 | £1,184,529 | |
| Average employees | 3 | 5 | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Current ratio | 0.19x | 0.62x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102 (Small Companies Regime)
- Reporting scope
- Consolidated group
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- Larking Gowen LLP
- Audit opinion
- Unaudited (audit-exempt)
- Going concern
- Affirmed
“At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and at least 12 months from the date of approval of the financial statements. Despite the loss for the year and the net liability position, the company will continue to receive funding in the next 12 months from third party grants, the directors and commonly controlled companies. The company has no excessive third party debt and the directors expect to receive further equity investments from wealthy individuals. Thus the directors continue to adopt the going concern basis of accounting in preparing financial statements.”
Group structure
- UROPHARMA, INC. · parent
- Uropharma Limited 100%
Significant events
- “During a previous period Uropharma, INC acquired the entire share capital of Uropharma Limited in share for share exchange.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 0 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| SHAPLAND, Howard Terence | Secretary | 2018-08-20 | — | — |
| GLICKMAN, Scott | Director | 2018-08-20 | Nov 1949 | American |
| SHAPLAND, Howard Terence | Director | 2018-08-20 | Jul 1943 | British |
Ownership
Persons with significant control
Filing timeline
Last 12 of 12 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-06 | OSCH01 | other | Change company details by uk establishment overseas company with change details | |
| 2025-11-11 | AA | accounts | Accounts with accounts type full | |
| 2024-12-11 | AA | accounts | Accounts with accounts type full | |
| 2024-02-12 | AA | accounts | Accounts with accounts type full | |
| 2022-07-28 | AA | accounts | Accounts with accounts type group | |
| 2022-02-11 | AA | accounts | Accounts with accounts type full | |
| 2020-09-15 | AA | accounts | Accounts with accounts type full | |
| 2019-10-09 | AA | accounts | Accounts with accounts type full | |
| 2019-09-30 | AA01 | accounts | Change account reference date company previous shortened | |
| 2019-02-27 | AA | accounts | Accounts with accounts type full | |
| 2018-08-20 | OS-PAR | annual-return | Appointment at registration of person authorised to represent | |
| 2018-08-20 | OSIN01 | incorporation | Register overseas company |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
+3.5%
£44,186 £45,742
-
Net assets
+402.9%
£235,551 £1,184,529
-
Employees
+66.7%
3 5
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers